-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 15, Kunyao Group issued an announcement stating that the company had received the "Drug Registration Certificate" (certificate number: 2021S00974) for valsartan and amlodipine tablets (I) issued by the State Drug Administration
Valsartan and Amlodipine Tablets (Ⅰ) are indicated for the treatment of essential hypertension and are used for monotherapy in patients who cannot adequately control blood pressure
In addition to the original Novartis, the major global manufacturers of the drug include MYLAN, TEVA, etc.
As of the date of this announcement, the company has invested approximately RMB 23.